Cerity Partners LLC Boosts Stock Position in Quaker Chemical Co. (NYSE:KWR)

Cerity Partners LLC boosted its position in Quaker Chemical Co. (NYSE:KWR - Free Report) by 485.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 64,631 shares of the specialty chemicals company's stock after buying an additional 53,592 shares during the period. Cerity Partners LLC owned approximately 0.36% of Quaker Chemical worth $10,890,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Fifth Third Bancorp boosted its holdings in shares of Quaker Chemical by 36.8% in the 2nd quarter. Fifth Third Bancorp now owns 286 shares of the specialty chemicals company's stock valued at $49,000 after acquiring an additional 77 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Quaker Chemical by 105.3% in the third quarter. GAMMA Investing LLC now owns 156 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 80 shares during the last quarter. Louisiana State Employees Retirement System grew its position in Quaker Chemical by 1.4% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,000 shares of the specialty chemicals company's stock worth $1,188,000 after purchasing an additional 100 shares during the period. Mackenzie Financial Corp raised its stake in shares of Quaker Chemical by 6.6% during the 2nd quarter. Mackenzie Financial Corp now owns 1,778 shares of the specialty chemicals company's stock valued at $302,000 after buying an additional 110 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of Quaker Chemical by 1.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 13,001 shares of the specialty chemicals company's stock valued at $2,191,000 after buying an additional 123 shares during the last quarter. Institutional investors and hedge funds own 77.46% of the company's stock.

Quaker Chemical Stock Performance

NYSE KWR opened at $157.81 on Wednesday. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of 23.14, a PEG ratio of 1.96 and a beta of 1.38. The stock has a 50-day moving average of $163.83 and a 200 day moving average of $169.66. The company has a current ratio of 2.54, a quick ratio of 1.88 and a debt-to-equity ratio of 0.48. Quaker Chemical Co. has a twelve month low of $151.31 and a twelve month high of $221.94.

Quaker Chemical (NYSE:KWR - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The specialty chemicals company reported $1.89 EPS for the quarter, missing analysts' consensus estimates of $2.08 by ($0.19). Quaker Chemical had a net margin of 6.58% and a return on equity of 10.10%. The business had revenue of $462.27 million during the quarter, compared to analysts' expectations of $469.17 million. During the same quarter last year, the firm earned $2.05 earnings per share. The firm's quarterly revenue was down 5.8% compared to the same quarter last year. Sell-side analysts anticipate that Quaker Chemical Co. will post 7.78 EPS for the current fiscal year.

Quaker Chemical Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, January 17th will be issued a dividend of $0.485 per share. This represents a $1.94 annualized dividend and a yield of 1.23%. The ex-dividend date of this dividend is Friday, January 17th. Quaker Chemical's payout ratio is 28.45%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Piper Sandler upped their target price on Quaker Chemical from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. StockNews.com lowered Quaker Chemical from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Quaker Chemical from $190.00 to $182.00 and set a "buy" rating for the company in a report on Monday, November 4th. Finally, Royal Bank of Canada lowered their price target on shares of Quaker Chemical from $195.00 to $180.00 and set an "outperform" rating on the stock in a report on Monday, November 4th.

Insider Activity

In other news, SVP David Slinkman sold 1,700 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $167.80, for a total value of $285,260.00. Following the transaction, the senior vice president now owns 2,825 shares in the company, valued at $474,035. This trade represents a 37.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jeewat Bijlani sold 645 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $165.98, for a total value of $107,057.10. Following the sale, the executive vice president now owns 4,747 shares of the company's stock, valued at $787,907.06. The trade was a 11.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Quaker Chemical Profile

Quaker Chemical Corporation, together with its subsidiaries, develops, produces, and markets various formulated specialty chemical products for a range of heavy industrial and manufacturing applications in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals.